Cargando…

Discovery of Novel Recurrent Mutations and Clinically Meaningful Subgroups in Nodal Marginal Zone Lymphoma

Nodal marginal zone lymphoma (NMZL) is a rare B-cell neoplasm, the genetic and transcriptomic landscape of which are unclear. Using high-throughput sequencing for whole-exome and transcriptome, we investigated the genetic characteristics of NMZL in a discovery cohort (n = 8) and validated their feat...

Descripción completa

Detalles Bibliográficos
Autores principales: Koh, Jiwon, Jang, Insoon, Choi, Seongmin, Kim, Sehui, Jang, Ingeon, Ahn, Hyun Kyung, Lee, Cheol, Paik, Jin Ho, Kim, Chul Woo, Lim, Megan S., Kim, Kwangsoo, Jeon, Yoon Kyung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352856/
https://www.ncbi.nlm.nih.gov/pubmed/32585984
http://dx.doi.org/10.3390/cancers12061669
_version_ 1783557736587329536
author Koh, Jiwon
Jang, Insoon
Choi, Seongmin
Kim, Sehui
Jang, Ingeon
Ahn, Hyun Kyung
Lee, Cheol
Paik, Jin Ho
Kim, Chul Woo
Lim, Megan S.
Kim, Kwangsoo
Jeon, Yoon Kyung
author_facet Koh, Jiwon
Jang, Insoon
Choi, Seongmin
Kim, Sehui
Jang, Ingeon
Ahn, Hyun Kyung
Lee, Cheol
Paik, Jin Ho
Kim, Chul Woo
Lim, Megan S.
Kim, Kwangsoo
Jeon, Yoon Kyung
author_sort Koh, Jiwon
collection PubMed
description Nodal marginal zone lymphoma (NMZL) is a rare B-cell neoplasm, the genetic and transcriptomic landscape of which are unclear. Using high-throughput sequencing for whole-exome and transcriptome, we investigated the genetic characteristics of NMZL in a discovery cohort (n = 8) and validated their features in an extended cohort (n = 30). Novel mutations in NFKBIE and ITPR2 were found in 7.9% (3/38) and 13.9% (5/36), respectively, suggesting roles for the NF-κB pathway and B-cell-receptor-mediated calcium signaling pathway in the pathogenesis of NMZL. RNA-seq showed that NMZLs were characterized by an aberrant marginal zone differentiation, associated with an altered IRF4-NOTCH2 axis and the enrichment of various oncogenic pathways. Based on gene expression profile, two subgroups were identified. Compared with subgroup 1, subgroup 2 showed the following: the significant enrichment of cell cycle-associated and MYC-signaling pathways, a more diverse repertoire of upstream regulators, and higher Ki-67 proliferation indices. We designated two subgroups according to Ki-67 labeling, and subgroup 2 was significantly associated with a shorter progression-free survival (p = 0.014), a greater proportion of large cells (p = 0.009), and higher MYC expression (p = 0.026). We suggest that NMZL has unique features and, in this study, we provide information as to the heterogeneity of this enigmatic entity.
format Online
Article
Text
id pubmed-7352856
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-73528562020-07-15 Discovery of Novel Recurrent Mutations and Clinically Meaningful Subgroups in Nodal Marginal Zone Lymphoma Koh, Jiwon Jang, Insoon Choi, Seongmin Kim, Sehui Jang, Ingeon Ahn, Hyun Kyung Lee, Cheol Paik, Jin Ho Kim, Chul Woo Lim, Megan S. Kim, Kwangsoo Jeon, Yoon Kyung Cancers (Basel) Article Nodal marginal zone lymphoma (NMZL) is a rare B-cell neoplasm, the genetic and transcriptomic landscape of which are unclear. Using high-throughput sequencing for whole-exome and transcriptome, we investigated the genetic characteristics of NMZL in a discovery cohort (n = 8) and validated their features in an extended cohort (n = 30). Novel mutations in NFKBIE and ITPR2 were found in 7.9% (3/38) and 13.9% (5/36), respectively, suggesting roles for the NF-κB pathway and B-cell-receptor-mediated calcium signaling pathway in the pathogenesis of NMZL. RNA-seq showed that NMZLs were characterized by an aberrant marginal zone differentiation, associated with an altered IRF4-NOTCH2 axis and the enrichment of various oncogenic pathways. Based on gene expression profile, two subgroups were identified. Compared with subgroup 1, subgroup 2 showed the following: the significant enrichment of cell cycle-associated and MYC-signaling pathways, a more diverse repertoire of upstream regulators, and higher Ki-67 proliferation indices. We designated two subgroups according to Ki-67 labeling, and subgroup 2 was significantly associated with a shorter progression-free survival (p = 0.014), a greater proportion of large cells (p = 0.009), and higher MYC expression (p = 0.026). We suggest that NMZL has unique features and, in this study, we provide information as to the heterogeneity of this enigmatic entity. MDPI 2020-06-23 /pmc/articles/PMC7352856/ /pubmed/32585984 http://dx.doi.org/10.3390/cancers12061669 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Koh, Jiwon
Jang, Insoon
Choi, Seongmin
Kim, Sehui
Jang, Ingeon
Ahn, Hyun Kyung
Lee, Cheol
Paik, Jin Ho
Kim, Chul Woo
Lim, Megan S.
Kim, Kwangsoo
Jeon, Yoon Kyung
Discovery of Novel Recurrent Mutations and Clinically Meaningful Subgroups in Nodal Marginal Zone Lymphoma
title Discovery of Novel Recurrent Mutations and Clinically Meaningful Subgroups in Nodal Marginal Zone Lymphoma
title_full Discovery of Novel Recurrent Mutations and Clinically Meaningful Subgroups in Nodal Marginal Zone Lymphoma
title_fullStr Discovery of Novel Recurrent Mutations and Clinically Meaningful Subgroups in Nodal Marginal Zone Lymphoma
title_full_unstemmed Discovery of Novel Recurrent Mutations and Clinically Meaningful Subgroups in Nodal Marginal Zone Lymphoma
title_short Discovery of Novel Recurrent Mutations and Clinically Meaningful Subgroups in Nodal Marginal Zone Lymphoma
title_sort discovery of novel recurrent mutations and clinically meaningful subgroups in nodal marginal zone lymphoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352856/
https://www.ncbi.nlm.nih.gov/pubmed/32585984
http://dx.doi.org/10.3390/cancers12061669
work_keys_str_mv AT kohjiwon discoveryofnovelrecurrentmutationsandclinicallymeaningfulsubgroupsinnodalmarginalzonelymphoma
AT janginsoon discoveryofnovelrecurrentmutationsandclinicallymeaningfulsubgroupsinnodalmarginalzonelymphoma
AT choiseongmin discoveryofnovelrecurrentmutationsandclinicallymeaningfulsubgroupsinnodalmarginalzonelymphoma
AT kimsehui discoveryofnovelrecurrentmutationsandclinicallymeaningfulsubgroupsinnodalmarginalzonelymphoma
AT jangingeon discoveryofnovelrecurrentmutationsandclinicallymeaningfulsubgroupsinnodalmarginalzonelymphoma
AT ahnhyunkyung discoveryofnovelrecurrentmutationsandclinicallymeaningfulsubgroupsinnodalmarginalzonelymphoma
AT leecheol discoveryofnovelrecurrentmutationsandclinicallymeaningfulsubgroupsinnodalmarginalzonelymphoma
AT paikjinho discoveryofnovelrecurrentmutationsandclinicallymeaningfulsubgroupsinnodalmarginalzonelymphoma
AT kimchulwoo discoveryofnovelrecurrentmutationsandclinicallymeaningfulsubgroupsinnodalmarginalzonelymphoma
AT limmegans discoveryofnovelrecurrentmutationsandclinicallymeaningfulsubgroupsinnodalmarginalzonelymphoma
AT kimkwangsoo discoveryofnovelrecurrentmutationsandclinicallymeaningfulsubgroupsinnodalmarginalzonelymphoma
AT jeonyoonkyung discoveryofnovelrecurrentmutationsandclinicallymeaningfulsubgroupsinnodalmarginalzonelymphoma